Member Info for ratcliffewriter

'Maybe you weren't referring to me?'

What makes you think I was referring to you? Do tell.

Well said crumbs, post rec. Your comment 'They are right until they are wrong' was never more true. The usual bile-spewing suspects arrive on cue, protesting their innocence and wisdom in equal proportions. They always sold at the top, bought at the bottom, knkw who holds what and at what average (actually hugjly amusing from my own standpoint) and have this innate wisdom born of their inner genius to know how well they perform when the rest of the plebs are simply a bunch of moronic losers, 'all in', 'under water', and 'lacking the virtues of the astute.'

The same ones who have manoeuvred their comments here from utter doom and gloom to 'if it goes well', allow wriggle room to have covered all eventualities for the future, and having some incredible insight into the purchase price and averages of others. Bear in mind sclp watchers have moved from hoping the next raise would not be excessively dilutive, to watching for how the current trials (plural) will look at their next results RNS, and debating just how lucrative the next MaB deal might be, or whether Covidity will attract a buyer/partner now or later. The same individuals who slated each BoD change as inadequate or irrelevant are now trying to hedge all bets and look like prophets of success while having more faces than a town hall clock in case of delayed news to help their day to day stance.

Crumbs - You may have to wait till trading opens tomorrow before you get a reply.

As long as LD isn't just going through the motions.

As long as it has the ring of truth.

When looking at the potential for competition it is probably worth remembering RG's genuine surprise and delight at the great breadth and scope of the patent granted to Moditope - the 'land grab.' They still hold that land very firmly, don't forget.

Bear in mind that when Scancell were pretty lonely developing immunotherapy for cancer, nobody was interested but they persevered to get to where they are now. When competition was mentioned, I remember RG saying there was room for several rivals in the same space. After all, Brunner and Mond didn't pack up and go home when IG Farben turned up, and Rolls and Royce developed cars despite the existing presence of La Buire and De Dion.

Agreed - and if it wasn't going to be a reasonably encouraging update (at the very minimum!) it would be extremely foolish to stick one's neck or other parts of the anatomy on the chopping block with media publicity in reputable papers (and The Guardian) ahead of it.

Remind me of the numbers enrolled and projected within the next 12 months for MOD1 please...?

The article doesn't sound like the words of a company with limited funds and a placing as the only option to replenish them. I could be wrong, but then crackin has popped up twice lately, and you know what that portends...

It's an old article, but reading it meant I wasn't clapping for a minute or two:

Observer reader profile

Fri 30 Apr 2010 15.45 BST

Reaching an affluent and young audience

Observer readers are affluent, young urban consumers with a keen sense of adventure when it comes to trying new products and experiences. They have varied interests and their high disposable incomes give them the means to keep up with their sports, hobbies and travel. Being difficult to reach through other media and newspapers, our readers make the Observer an extremely valuable title to include on your schedule.

Well-travelled

Observer readers love to splash out on holidays and particularly on weekends away (spending £570 on a typical short break vs the £430 spent by the average consumer). They enjoy a wide variety of holidays, but are particularly keen on city breaks, lakes and mountains holidays, ski trips and spa weekends. They fly more often than the average consumer, are more likely to book flights directly with the airline and to upgrade from economy class.

Finance-savvy

Observer readers are affluent individuals who earn a third more than average. They are more likely to talk knowledgeably about financial services to others, to read the financial pages of their newspaper and to invest in stocks and shares. On average they spend around £400 a month on their credit cards and are likely to use them frequently to pay for eating out as well as booking travel and hotels.

'I was looking up pictures of tractors, honest love. Just like that MP the other year.'

Agreed - not wanting to set too much store by it, but LD would never imo bother mentioning Nasdaq unless it was on the agenda.

The usual 'astute' and 'balanced' posters obviously having a lie-in this morning, or maybe they're at church.

Given the frustratingly normal radio silence we have had since February, I don't believe that an individual as reserved as LD would feature in a high profile interview in a broadsheet Sunday paper if she knew the next set of trial data was going to be anything other than promising, or somewhere between respectable and 'knock your socks off'. We won't known till we are told, but that's how it seems to me.

Just check there isn't a thin tail hanging out of the end of the sausage roll....

She says she started on the trial just a few days ago, so whichever cohort I take it that all dose escalation and introduction of checkpoint inhibitors is on schedule and remaining tolerable at the absolute minimum. As with almost everyone here, I'm keen to see what the next set of data tells us.

Further comment on the Macmillan blog. Seems there is a considerable reaction to the injection, which means that the DTH is almost immediate and significant. We know LD was very pleased at a similar reaction in all earlier patients - does this raise hopes of a favourable response in all patients in-between?

Agreed Krafty. And on a different note, the blog is publicly available and imo fine to quote, but otherwise leave well alone if you get my drift.

Also, I wonder if Scancell will have any 'editorial

input' so to speak?

Anyway, looks as if recruiting is going well and spaces are in short supply - here's hoping the patient thrives for the usual range of reasons.

Amazing what mice experiments can achieve.

https://youtu.be/tPg6lnYtTRQ